Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 10k
15 January 2020
Question for written answer E-000211/2020
to the Commission
Rule 138
Bernhard Zimniok (ID)
 Answer in writing 
 Subject: Bottlenecks in the supply of medicines

In Germany, hospitals and pharmacies have for some time been complaining about shortages in the supply of medicines, some of which are important and relevant to hospitals. The Federal Institute for Drugs and Medical Devices maintains a list of them on its website, which is updated daily (1) .

Germany’s federation of pharmaceutical wholesalers (PHAGRO) believes that the main reasons for the shortage of supplies are relocation of production outside Europe, which is concentrated in a small number of production sites, and the ever-increasing demand for pharmaceuticals worldwide.

1. Is the Commission aware of such supply shortages in other Member States, i.e. can this be defined as an EU-wide problem?

2. Has the Commission devised a single European strategy to address this problem and if so, what is the nature of this strategy?

3. What strategies has the Commission formulated to ensure the health of citizens in the event of a worst-case scenario (long-term shortages of essential medicines)?

Original language of question: DE
Last updated: 25 September 2020Legal notice - Privacy policy